Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis

Bettegowda, 2014, Detection of circulating tumor DNA in early- and late-stage human malignancies, Science Translational Medicine, 6, 10.1126/scitranslmed.3007094 Bronkhorst, 2015, Cell-free DNA: Preanalytical variables, Clinica Chimica Acta, 450, 243, 10.1016/j.cca.2015.08.028 Chabon, 2016, Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients, Nature Communications, 7, 11815, 10.1038/ncomms11815 Chan, 2013, Cancer genome scanning in plasma: Detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing, Clinical Chemistry, 59, 211, 10.1373/clinchem.2012.196014 Dawson, 2013, Analysis of circulating tumor DNA to monitor metastatic breast cancer, The New England Journal of Medicine, 368, 1199, 10.1056/NEJMoa1213261 De Mattos-Arruda, 2015, Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma, Nature Communications, 6, 8839, 10.1038/ncomms9839 De Mattos-Arruda, 2014, Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle, Annals of Oncology, 25, 1729, 10.1093/annonc/mdu239 Devonshire, 2014, Towards standardisation of cell-free DNA measurement in plasma: Controls for extraction efficiency, fragment size bias and quantification, Analytical and Bioanalytical Chemistry, 406, 6499, 10.1007/s00216-014-7835-3 Diaz, 2012, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, 486, 537, 10.1038/nature11219 Diehl, 2008, Circulating mutant DNA to assess tumor dynamics, Nature Medicine, 14, 985, 10.1038/nm.1789 Forshew, 2012, Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA, Science Translational Medicine, 4, 10.1126/scitranslmed.3003726 Hata, 2016, Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, Nature Medicine, 22, 262, 10.1038/nm.4040 Jamal-Hanjani, 2016, Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer, Annals of Oncology, 27, 862, 10.1093/annonc/mdw037 Jiang, 2015, Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients, Proceedings of the National Academy of Sciences of the United States of America, 112, E1317, 10.1073/pnas.1500076112 Kinde, 2011, Detection and quantification of rare mutations with massively parallel sequencing, Proceedings of the National Academy of Sciences of the United States of America, 108, 9530, 10.1073/pnas.1105422108 Kuczynski, 2013, Drug rechallenge and treatment beyond progression—Implications for drug resistance, Nature Reviews. Clinical Oncology, 10, 571, 10.1038/nrclinonc.2013.158 Lanman, 2015, Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA, PloS One, 10, 10.1371/journal.pone.0140712 Li, 2008, Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing, Nature Medicine, 14, 579, 10.1038/nm1708 LoRusso, 2015, Pilot trial of selecting molecularly guided therapy for patients with non-V600 BRAF-mutant metastatic melanoma: Experience of the SU2C/MRA melanoma dream team, Molecular Cancer Therapeutics, 14, 1962, 10.1158/1535-7163.MCT-15-0153 McGranahan, 2015, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, Cancer Cell, 27, 15, 10.1016/j.ccell.2014.12.001 McNeil, 2015, NCI-MATCH launch highlights new trial design in precision-medicine era, Journal of the National Cancer Institute, 107, 10.1093/jnci/djv193 Misale, 2012, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, 486, 532, 10.1038/nature11156 Murtaza, 2015, Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer, Nature Communications, 6, 8760, 10.1038/ncomms9760 Murtaza, 2013, Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA, Nature, 497, 108, 10.1038/nature12065 Newman, 2016, Integrated digital error suppression for improved detection of circulating tumor DNA, Nature Biotechnology, 34, 547, 10.1038/nbt.3520 Norton, 2013, A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR, Clinical Biochemistry, 46, 1561, 10.1016/j.clinbiochem.2013.06.002 Oxnard, 2016, Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer, Journal of Clinical Oncology, 34, 3375, 10.1200/JCO.2016.66.7162 Siravegna, 2015, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nature Medicine, 21, 795, 10.1038/nm.3870 Sundaresan, 2016, Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses, Clinical Cancer Research, 22, 1103, 10.1158/1078-0432.CCR-15-1031 Tannock, 2016, Limits to personalized cancer medicine, The New England Journal of Medicine, 375, 1289, 10.1056/NEJMsb1607705 Thierry, 2014, Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nature Medicine, 20, 430, 10.1038/nm.3511 Thompson, 2012, Winnowing DNA for rare sequences: Highly specific sequence and methylation based enrichment, PloS One, 7, 10.1371/journal.pone.0031597 Thress, 2015, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nature Medicine, 21, 560, 10.1038/nm.3854 Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122